# Very Early PCSK9 Inhibition for Acute Myocardial Infarction

> **NCT07208006** · NA · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 1518 (estimated)

## Conditions studied

- Acute Myocardial Infarction (AMI)

## Interventions

- **DRUG:** Standard Lipid-Lowering Therapy
- **DRUG:** Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)

## Key facts

- **NCT ID:** NCT07208006
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 1518 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208006, "Very Early PCSK9 Inhibition for Acute Myocardial Infarction". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07208006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*